Meet our partners
Europe Partner
Johnson & Johnson Innovation
Johnson & Johnson Innovation’s goal is to advance transformative healthcare solutions that deliver value and improve people’s lives around the world by catalysing new science and technology through collaboration and exchange of ideas. At each innovation centre, Johnson & Johnson Innovation’s experts offer a diverse range of knowledge and resources to help innovators at universities, academic institutes and start-up biotech companies. Read more at

Jan 2016 Inivata Completes £31.5 Million ($45M) Series A Fundraising Round

Nov 2015 Overseas Businesswoman of the Year Award: Dr Jeanne Bolger, vice president of investment ventures, Johnson & Johnson

Oct 2015 J&J's Ethicon partners with Fogarty Institute to back next-gen device innovation

OneStart Europe Vision Film 2016 

        • Jeanne Bolger, VP Venture Investing, Johnson & Johnson Innovation - JJDC
        • Richard Mason, Head of Johnson & Johnson Innovation London, Johnson & Johnson 
        • Dan Perez, CEO & Founder, Oxbridge Biotech Roundtable 
        • Nooman Haque, Director of Life Sciences, Silicon Valley Bank
        • Matthew Foy, Partner, SR One
        • Sarah Haywood, CEO, MedCity 
        • Matthias Essenpreis, CTO (Diagnostics), F-Hoffman-La Roche Ltd. 
        • Rachel Moss, Associate Principal, McKinsey and Company 
        • Claire Brown, Investment Manager, Alderley Park Ventures / BioCity 
        • Lynne Murray, Partnering and Strategy, MedImmune
        • Aric Orbach, Head of Pharmacology, Teva Pharmaceutical Industries 
        • Stephen Reese, Partner, Olswang LLP 
        • Ilan Zipkin, Investment Director, Takeda Ventures Inc. 

        From the OneStart London Bootcamp 2016 


        Seminar: Writing a Good Business Plan - Jeanne Bolger

        • Jeanne Bolger, VP Venture Investing, Johnson & Johnson Innovation - JJDC

        Seminar: Business Model Innovation
        • Richard Mason, PhD, Head of Johnson & Johnson Innovation, London, Johnson & Johnson Innovation 
        • Sonal Patel, External Innovation Group, Roche 
        • Craig Rhodes, Business Innovation Manager in Health and Life Sciences, Intel Corporation 

        Panel Discussion 

        Panel Discussion: Accessing and Interacting with Industry

        • Rachel Moss, PhD, Associate Principal, McKinsey & Company (Chair)
        • Elena Fernandez Kleinlein, Senior Director, Consumer Scientific Innovation, Johnson & Johnson Innovation, London
        • Georg Buchner, PhD and MBA, Licensing Director, Amgen
        • Will West, PhD, President & CEO, Cancer Targeting System Inc.
        • Claire Brown, PhD, Investment Manager, Alderley Park Ventures
        • Aric Orbach, DVM, Head of Pharmacology. Teva Pharmaceuticals

        From the OneStart San Francisco Bootcamp 2016 

        Panel Discussion

        Panel Discussion: Accessing and Interacting with Industry
        • Thomas Luby, PhD, Senior Director of New Ventures, Johnson & Johnson innovation, Boston (Chair)
        • Lucy Perez, PhD, Partner, McKinsey and Company
        • Sam Wu, Managing Director, MedImmune Ventures
        • Sharon Cload, VP Molecular Discovery Technologies, Bristol-Myers Squibb
        • David Wilson, PhD, VP Biologics, Teva Pharmaceuticals

        From the OneStart London Bootcamp 2015 

        Panel Discussion

        Panel Discussion: Case Studies from Life Science Companies

        • Jeanne Bolger, VP Venture Investing, Johnson & Johnson Innovation- JJDC (Chair)
        • Ilan Zipkin, PhD, Senior Investment Director, Takeda Ventures
        • Chris Brown, MBA, Director, Scientific Licensing, Worldwide Business Development, GSK
        • Sarah Holland, DPhil(Oxon), MBA, Life Cycle Leader alectinib, Roche
        • Lynne Murray, PhD, MBA, Partnering & Strategy, MedImmune

        Panel Discussion: Life Science & Healthcare Investors

        • Matthew Foy, Partner, SR One (Chair)
        • Maina Bhaman, Director of Healthcare Investments, Imperial Innovations
        • Jeanne Bolger, VP Venture Investing, Johnson & Johnson Innovation- JJDC
        • Vishal Gulati, MD, Venture Partner, DFJ Esprit
        • Deborah Harland, PhD, MBA, Partner, SR One
        • Ilan Zipkin, PhD, Senior Investment Director, Takeda Ventures
        Thomas Luby
        Senior Director, New Ventures, Johnson & Johnson Innovation, Boston + more
        I focus primarily on cardiovascular & metabolic; infectious diseases and vaccines; and neurobiology. Prior to joining Johnson & Johnson, I was Senior Director of Research Ventures at Shire Human Genetic Therapies.
        Alan Ashby
        VP, Global Concept Development, DePuy - a Johnson & Johnson Company + more
        I am VP of Global Concept Development at DePuy Synthes, a Johnson & Johnson Company and and global leaders in providing healthcare solutions in orthopaedics, spinal care, sports medicine and neurosciences.
        Declan Jones
        VP Neuroscience Scientific Innovation, Johnson & Johnson Innovation London + more
        I am Vice President of Neuroscience Scientific Innovation at Johnson & Johnson Innovation London. I previously worked for GSK’s Centre of Excellence for External Drug Discovery (CEEDD) where I was responsible for creating scientific strategies and managing processes from preclinical to Phase II state programs across all therapeutic areas.
        Elena Fernandez-Kleinlein
        Senior Director, Consumer Scientific Innovation, Johnson & Johnson Innovation, London + more
        I am Senior Director of Consumer Scientific Innovation at Johnson & Johnson Innovation, London. Previously as Senior Director of R&D Global Topical Health Care for Johnson & Johnson Consumer & Personal Products, I was responsible for seeking innovative products and claims pipelines within the franchise and oversaw the product development program for iconic brands such as Band-Aid Adhesive Bandages, Johnson & Johnson’s Red Cross and other regional brands like Compeed, Neosporin and Bengay.
        Johan Verbeeck
        Senior Director, Partnership Management, Johnson & Johnson Innovation, London + more
        I am Senior Director of Partnership Management at Johnson & Johnson Innovation, London. Previously, I was Director of Toxicology at Tibotec where I worked on the development of Prezista and Intelence, Tibotec’s first two approved anti-HIV drugs. After the approval of Intelence, I transferred to North America to become Head of Toxicology Sciences for Janssen at the Raritan, NJ site.
        Karin Conde-Knape
        Vice President of Cardiovascular & Metabolic Scientific Innovation, Johnson & Johnson Innovation, London + more
        I am VP Cardiovascular & Metabolic Scientific Innovation at Johnson & Johnson Innovation, London. Previously, I was Global Head of Discovery in the CVM DTA at Roche where I was responsible for all the Early Research efforts as well as the Translational Biomarker and experimental medicine group. While at Roche, I was responsible for identifying and managing numerous external collaborations with well renowned institutions worldwide.
        Kurt Hertogs
        Platform Innovation & Incubator Strategy Leader, Johnson & Johnson Innovation, London. + more
        I am Platform Innovation & Incubator Strategy Leader at Johnson & Johnson Innovation, London. Previously, I held research and early stage development roles at Tibotec and was involved in the discovery and pharmacological profiling of major anti-infective drugs like Prezista, Intellence, Edurant, Incivo and Simeprevir.
        Roger Bone
        Vice President of Transactions, Johnson & Johnson Innovation, London + more
        I am Vice President of Transactions at Johnson & Johnson Innovation, London. Prior to this role, Roger was Vice President Scientific Affairs within New Ventures business development. I was formerly Global Head, Research Capabilities with responsibility for chemistry and enabling technologies supporting therapeutic area discovery efforts.
        Yelda Kaya
        Senior Director Transactions, Johnson & Johnson Innovation, London + more
        I have an extensive background in life sciences with previous roles in worldwide business development at GSK, as a corporate lawyer and emergency medicine clinician.
        Saurin Badiyani
        Healthcare Solutions Lead at The Janssen Pharmaceutical Companies of Johnson & Johnson + more
        Healthcare innovation professional with interdisciplinary applied research, product prototype & service development, consulting and business development experience gained throughout Europe. Managed multiple concurrent projects from ideation to completion spanning across multiple industry verticals including IT, healthcare, pharma, biotech and manufacturing. Managed multiple concurrent projects from ideation to completion; including financial, operational and strategic planning and management.
        Yiu-Lian Fong
        Global Diagnostic Innovation, Johnson & Johnson Innovation + more
        20 years of broad and progressive management and leadership roles in IVD, pharmaceutical and biotechnology industry. Extensive experiences in R&D leadership roles for portfolio / program / project / people management, strategic planning and execution for IVD, Blood Screening, protein therapeutics and vaccines, and for technology development. Proven track record of establishing R&D functional excellences, developing innovative technologies and directing/leading technical due diligence for M&A and licensing; managing R&D budgets, directing and managing multidisciplinary teams and functional departments, advancing R&D pipelines, and meeting/exceeding organization and program objectives. Track record of building talent pipelines and extensive experience in talent management. Experiences and roles/responsibilities include: • Develop and/or execute business strategies for genetics, oncology, infectious disease, metabolic disease, and neuroscience •Develop and drive technical strategies for drug and companion diagnostics co-development • Recruit and develop talents, build functional departments and project teams, develop and implement product development and project management tools and processes, grow organization. • Direct, manage and oversee R&D functions for biological drug and vaccine development, blood screening, and IVD product development: Biomarker Development, Assay Development, System and SW Engineering, System Integration, Design Transfer, Technology Transfer, Technology Development, Process Development and Validation, Pilot Production, Analytical Method Development and Method Validation, QC Testing, Project Management (PMO) and Scientific Affairs. •Drug development CMC lead or core team member: Phase I, II and III IND, and NDA/BLA submissions for biological and blood screening. •Technology assessments and strategic alignment for M&A and BDL initiatives •Strategic alliance with partners and vendors, drive and manage collaborations
        Laurent Morlet
        Digital Innovation at Johnson & Johnson Innovation + more
        Laurent is Digital Innovation Lead at Johnson & Johnson Innovation, London. Previously, Laurent helped the Janssen Drug Evaluation group manage scientific information and information systems. Laurent was also a Business Relationship Manager working with different business units over time. Laurent holds a PhD in Pharmaceutical Sciences from the University of Nantes, France. He has also gained additional diplomas in photobiology and drug delivery systems.
        Widya Mulyasasmita
        Senior Associate, New Ventures at Johnson & Johnson Innovation + more
        Widya joined Johnson & Johnson Innovation, California as part of the New Ventures team, supporting deals and collaborations across consumer, medical device and pharmaceutical sectors. Widya comes to Johnson & Johnson from McKinsey & Company, where she was a management consultant advising clients in healthcare and other industries on corporate strategy, lean operations, and organizational health topics. Prior to McKinsey, Widya worked at GE Ventures Healthcare as an Associate Intern, and she also co-founded a medical device startup called LapIQ, where she served as Chief Scientist developing biodegradable wound closure devices.
        Anthony Gemmell
        Senior Director, Transactions, Johnson & Johnson + more
        Anthony is Senior Director of Transactions for Johnson & Johnson Innovation, London. Previously, Anthony worked within several business development roles in Johnson & Johnson Pharmaceutical Group Business Development including New Business Development, Mergers & Acquisitions and New Ventures, and has completed a wide variety of business development, licensing, acquisition and divestment assignments. Prior to joining the Johnson & Johnson Family of Companies, Anthony had management roles in the UK and EMEA in New Product Development and Business Unit Management with Lilly, Servier and Bristol Myers Squibb spanning multiple disease areas. He started his career teaching Biological Sciences in secondary education.
        Lilian Alcaraz
        Senior Director, Medicinal Chemistry Lead, Johnson & Johnson Innovation + more
        Lilian is the Medicinal Chemistry Lead, for Johnson & Johnson Innovation, London Lilian has over 16 years’ experience in Medicinal Chemistry gained through working in both large pharma and CRO environments. Before joining Johnson & Johnson Innovation, Lilian was Senior Director of Chemistry at Charles River (Argenta). In this role, he co-headed of the chemistry department and was the Collaboration Leader of a large multidisciplinary tri-party partnership overseeing the delivery of multiple drug discovery projects. Prior to that, Lilian spent 13 years at AstraZeneca advancing in various leadership roles culminating as a Principal Scientist. During his time at AstraZeneca, Lilian gained extensive experience in lead optimization, lead identification and library design and synthesis. He was a member of the milestone review group for Respiratory and Inflammation research area and led improvement projects aimed at enhancing strategic component of Candidate Drug Discovery.
        Jeanne Bolger
        Vice President Venture Investing at Johnson & Johnson + more
        VP Investor with JJDC, Johnson & Johnson's Corporate Venture firm.. Based at the London Innovation Centre. Focus on investments in early to late stage pharmaceuticals / biotech companies in areas of strategic interest to Johnson & Johnson.
        Teams Mentored